drugset / Trial / NCT05132660

Treating Early Stage Diabetic Retinopathy

NCT05132660

Phase 0 Enrolling by invitation 244 enrolled VA Office of Research and Development Emory University · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine if levodopa will slow the appearance of blood vessel changes in the eyes of patients with diabetes. Treatment will be started in patients with diabetes show delays in the electrical activity of the retina when measured non-invasively with a electroretinogram.

Timeline

Start
2022-07-01
Primary completion
2027-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Levodopa Small molecule 100 mg
Background Carbidopa Unknown 25 mg

Indications